Johnson & Johnson

Latest Headlines

Latest Headlines

Forest pins new hopes on Bystolic with rights buyout

Forest Laboratories has bought full rights to a blood-pressure drug co-marketed with Johnson & Johnson.

MHRA urges docs to avoid some metal hips

The bad news just keeps on coming in for manufactures of metal-on-metal hips. This morning, Johnson & Johnson ($JNJ) and Stryker ($SYK) are feeling the heat from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA).

An Etch-a-Sketch picture of J&J CEO-to-be Alex Gorsky

Gorsky hasn't been made available to the media, but colleagues say he's a strong leader and a good communicator.

UPDATED: Dendreon's Provenge faces new questions

A new article questions the effectiveness of Dendreon's prostate cancer drug Provenge.

California implant makers get FDA warnings

Two Murrieta, CA-based implant makers have been called on the carpet by the FDA for lacking quality control over their manufacturing or assembling processes.

Arkansas jury hears state's claims against J&J

The state claims the company misled doctors about Risperdal and is seeking $1.25 billion in penalties.

J&J's Risperdal cases head to court in Texas, Arkansas

As Johnson & Johnson and the state of Arkansas start airing their arguments over Risperdal marketing, the company is going back to court in Texas, where it agreed to pay $158 million to settle a...

FDA seeks advice on making more drugs OTC

The FDA is holding its second day of hearings on whether some prescription medications should become sold OTC.

Merck to invest in Canadian VC fund

It takes money to make money and yet another pharmaceutical maker is partnering in a venture capital fund, this one designed to draw drug companies to Quebec.

UPDATED: Merck drug homes in on new baldness target

Drug developers have a new target to pursue in their search for remedies against baldness, which afflicts most males to some degree.